Tyrosine kinase inhibitors (TKIs) combined with immunotherapy have improved outcomes in advanced renal cell carcinoma (aRCC), yet resistance persists. This group presents single-cell transcriptomic profiling of aRCC patients treated with TKIs and immune checkpoint inhibitors, uncovering an immunosuppressive microenvironment linked to therapeutic resistance.
- Liangyou Gu
- Qi Zhang
- Baojun Wang
